(UroToday.com) The QuEST1 trial was designed to rapidly interrogate the safety and efficacy of a combination of immunotherapy regiments and see the activity of immunotherapy in castrate-resistant prostate cancer (CRPC).
The analyzed regimen in the presented study (Figure 1) included three factors: